Terms: = Ovarian cancer AND MAX, MGC36767, 4149, ENSG00000125952, MGC18164, MGC10775, P61244, MGC11225, orf1, MGC34679 AND Treatment
61 results:
1. A Relative Bioavailability, Bioequivalence, and Food Effect Study of Niraparib Tablets in Patients with Advanced Solid Tumors.
Falchook G; Patnaik A; Richardson DL; Harvey RD; Sharma MR; Hafez N; Hamilton E; Piha-Paul SA; Barve M; Wise-Draper T; Patel MR; Dowlati A; Pascuzzo J; Tang SC; Faltermeier C; Malinowska IA; Shtessel L; Striha A; Potocka E
Clin Ther; 2024 Mar; 46(3):228-238. PubMed ID: 38423866
[TBL] [Abstract] [Full Text] [Related]
2. CXCR4-directed PET/CT with [
Dreher N; Hahner S; Fuß CT; Schlötelburg W; Hartrampf PE; Serfling SE; Schirbel A; Samnick S; Higuchi T; Weich A; Lapa C; Rosenwald A; Buck AK; Kircher S; Werner RA
Eur J Nucl Med Mol Imaging; 2024 Apr; 51(5):1383-1394. PubMed ID: 38082196
[TBL] [Abstract] [Full Text] [Related]
3. Benefits of Soybean in the Era of Precision Medicine: A Review of Clinical Evidence.
Kang JH; Dong Z; Shin SH
J Microbiol Biotechnol; 2023 Dec; 33(12):1552-1562. PubMed ID: 37674385
[TBL] [Abstract] [Full Text] [Related]
4. A comparative study of [
Xi Y; Sun L; Che X; Huang X; Liu H; Wang Q; Meng H; Miao Y; Qu Q; Hai W; Li B; Feng W
Eur J Nucl Med Mol Imaging; 2023 Jul; 50(9):2885-2898. PubMed ID: 37093313
[TBL] [Abstract] [Full Text] [Related]
5. Systemic exposure to cisplatin and paclitaxel after intraperitoneal chemotherapy in ovarian cancer.
de Jong LAW; Lambert M; van Erp NP; de Vries L; Chatelut E; Ottevanger PB
Cancer Chemother Pharmacol; 2023 Mar; 91(3):247-256. PubMed ID: 36892677
[TBL] [Abstract] [Full Text] [Related]
6. Discovery of Highly Potent Nicotinamide Phosphoribosyltransferase Degraders for Efficient treatment of ovarian cancer.
Bi K; Cheng J; He S; Fang Y; Huang M; Sheng C; Dong G
J Med Chem; 2023 Jan; 66(1):1048-1062. PubMed ID: 36563407
[TBL] [Abstract] [Full Text] [Related]
7. 68 Ga-Prostate-Specific Membrane Antigen PET/CT in ovarian Tumors : Potential to Differentiate Benign and Malignant Tumors Before Surgery: A Preliminary Report.
Kunikowska J; Bizoń M; Pełka K; Derlatka P; Olszewski M; Królicki L
Clin Nucl Med; 2023 Feb; 48(2):e60-e66. PubMed ID: 36512649
[TBL] [Abstract] [Full Text] [Related]
8. Risk of thrombosis in women with cancer undergoing controlled ovarian hyperstimulation for fertility preservation.
Melo VD; Liseth OY; Schmidt WM; Pruthi RK; Marshall AL; Shenoy CC
J Assist Reprod Genet; 2022 Dec; 39(12):2847-2856. PubMed ID: 36427171
[TBL] [Abstract] [Full Text] [Related]
9. Spatial-Temporal Trends in ovarian cancer Outcomes in California.
Villanueva C; Chang J; Ziogas A; Bristow RE; Vieira VM
JNCI Cancer Spectr; 2022 Nov; 6(6):. PubMed ID: 36238987
[TBL] [Abstract] [Full Text] [Related]
10. Bioequivalence of a hybrid pegylated liposomal doxorubicin hydrochloride injection and Caelyx®: A single-dose, randomized, multicenter, open-label, two-period crossover study in patients with advanced ovarian cancer.
S PS; Nagarkar RV; Puligundla KC; N LK; Boya RR; Patel AB; Goyal L; Thoke A; Patel JG; Mehta AO; Patel GN; Khan MA; Ahmad I
Eur J Pharm Sci; 2022 Sep; 176():106248. PubMed ID: 35777616
[TBL] [Abstract] [Full Text] [Related]
11. The Healthcare Journey of Women With Advanced Gynecological cancer From Diagnosis Through Terminal Illness: Qualitative Analysis of Progress Note Data.
Dillon EC; Chopra V; Mesghina E; Milki A; Chan A; Reddy R; Kapp DS; Silver BA; Chan JK
Am J Hosp Palliat Care; 2022 Sep; 39(9):1090-1097. PubMed ID: 34951820
[TBL] [Abstract] [Full Text] [Related]
12. Effect of fluconazole on the pharmacokinetics of fuzuloparib: an open-label, crossover study in Chinese healthy male volunteers.
Chen X; Yang F; Zhao J; Tang Q; Heng J; Deng J; Zhang J; Chen Y; Li K; Wang J
Cancer Chemother Pharmacol; 2022 Jan; 89(1):141-148. PubMed ID: 34851444
[TBL] [Abstract] [Full Text] [Related]
13. Pharmacokinetics and safety of rucaparib in patients with advanced solid tumors and hepatic impairment.
Grechko N; Skarbova V; Tomaszewska-Kiecana M; Ramlau R; Centkowski P; Drew Y; Dziadziuszko R; Zemanova M; Beltman J; Nash E; Habeck J; Liao M; Xiao J
Cancer Chemother Pharmacol; 2021 Aug; 88(2):259-270. PubMed ID: 33909097
[TBL] [Abstract] [Full Text] [Related]
14. Population exposure-efficacy and exposure-safety analyses for rucaparib in patients with recurrent ovarian carcinoma from Study 10 and ARIEL2.
Konecny GE; Oza AM; Tinker AV; Oaknin A; Shapira-Frommer R; Ray-Coquard I; Aghajanian C; Coleman RL; O'Malley DM; Leary A; Chen LM; Provencher D; Ma L; Brenton JD; Castro C; Green M; Simmons AD; Beltman J; Harding T; Lin KK; Goble S; Maloney L; Kristeleit RS; McNeish IA; Swisher EM; Xiao JJ
Gynecol Oncol; 2021 Jun; 161(3):668-675. PubMed ID: 33752918
[TBL] [Abstract] [Full Text] [Related]
15. Phase 2 single-arm study on the safety of maintenance niraparib in Japanese patients with platinum-sensitive relapsed ovarian cancer.
Takehara K; Matsumoto T; Hamanishi J; Hasegawa K; Matsuura M; Miura K; Nagao S; Nakai H; Tanaka N; Tokunaga H; Ushijima K; Watari H; Yokoyama Y; Kase Y; Sumino S; Suri A; Itamochi H; Takeshima N
J Gynecol Oncol; 2021 Mar; 32(2):e21. PubMed ID: 33470063
[TBL] [Abstract] [Full Text] [Related]
16. Dose-dependent cell cycle arrest and apoptosis in HER2 breast cancer cells by
Sharma R; Kameswaran M; Pandey U; Dash A
J Cancer Res Ther; 2020; 16(6):1426-1434. PubMed ID: 33342808
[TBL] [Abstract] [Full Text] [Related]
17. TRAINING-Ovary 01 (connecTed pRehabiliAtIoN pelvIc cancer surGery): multicenter randomized study comparing neoadjuvant chemotherapy for patients managed for ovarian cancer with or without a connected pre-habilitation program.
Lambaudie E; Bannier/Braticevic C; Villaron/Goetgheluck C; Zemmour C; Boher JM; Ben Soussan P; Pakradouni J; Brun C; Lopez Almeida L; Marino P
Int J Gynecol Cancer; 2021 Jun; 31(6):920-924. PubMed ID: 33262113
[TBL] [Abstract] [Full Text] [Related]
18. CUP-AI-Dx: A tool for inferring cancer tissue of origin and molecular subtype using RNA gene-expression data and artificial intelligence.
Zhao Y; Pan Z; Namburi S; Pattison A; Posner A; Balachander S; Paisie CA; Reddi HV; Rueter J; Gill AJ; Fox S; Raghav KPS; Flynn WF; Tothill RW; Li S; Karuturi RKM; George J
EBioMedicine; 2020 Nov; 61():103030. PubMed ID: 33039710
[TBL] [Abstract] [Full Text] [Related]
19. Multisite Tumor Sampling Reveals Extensive Heterogeneity of Tumor and Host Immune Response in ovarian cancer.
Lakis S; Kotoula V; Koliou GA; Efstratiou I; Chrisafi S; Papanikolaou A; Zebekakis P; Fountzilas G
Cancer Genomics Proteomics; 2020; 17(5):529-541. PubMed ID: 32859631
[TBL] [Abstract] [Full Text] [Related]
20. Monitoring the Crosstalk Between the Estrogen Receptor and Human Epidermal Growth Factor Receptor 2 with PET.
Antunes IF; Hospers GAP; Sijbesma JWA; Boerema AS; van Waarde A; Glaudemans AWJM; Dierckx RAJO; de Vries EGE; de Vries EFJ
Mol Imaging Biol; 2020 Oct; 22(5):1218-1225. PubMed ID: 32285356
[TBL] [Abstract] [Full Text] [Related]
[Next]
